CL2011001812A1 - Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. - Google Patents

Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.

Info

Publication number
CL2011001812A1
CL2011001812A1 CL2011001812A CL2011001812A CL2011001812A1 CL 2011001812 A1 CL2011001812 A1 CL 2011001812A1 CL 2011001812 A CL2011001812 A CL 2011001812A CL 2011001812 A CL2011001812 A CL 2011001812A CL 2011001812 A1 CL2011001812 A1 CL 2011001812A1
Authority
CL
Chile
Prior art keywords
degeneration
deferiprone
cataracts
glaucoma
retinopathy
Prior art date
Application number
CL2011001812A
Other languages
English (en)
Spanish (es)
Inventor
Michael Dunaief Joshua Lawrence Spino
Original Assignee
Spino Michael
Dunaief Joshua Lawrence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spino Michael, Dunaief Joshua Lawrence filed Critical Spino Michael
Publication of CL2011001812A1 publication Critical patent/CL2011001812A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2011001812A 2009-01-26 2011-07-26 Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. CL2011001812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14724509P 2009-01-26 2009-01-26

Publications (1)

Publication Number Publication Date
CL2011001812A1 true CL2011001812A1 (es) 2012-02-03

Family

ID=42355449

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001812A CL2011001812A1 (es) 2009-01-26 2011-07-26 Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.

Country Status (24)

Country Link
US (1) US20130023569A1 (fr)
EP (1) EP2389179A4 (fr)
JP (1) JP5604631B2 (fr)
KR (1) KR20120078667A (fr)
CN (1) CN102348456A (fr)
AP (1) AP2011005843A0 (fr)
AU (1) AU2009338093B2 (fr)
BR (1) BRPI0920492A2 (fr)
CA (1) CA2750599A1 (fr)
CL (1) CL2011001812A1 (fr)
CR (1) CR20110456A (fr)
EA (1) EA201170970A1 (fr)
IL (1) IL214291A (fr)
MA (1) MA33090B1 (fr)
MX (1) MX2011007947A (fr)
MY (1) MY161269A (fr)
NI (1) NI201100148A (fr)
NZ (1) NZ594728A (fr)
PE (1) PE20120515A1 (fr)
SG (1) SG173145A1 (fr)
TN (1) TN2011000366A1 (fr)
UA (1) UA103366C2 (fr)
WO (1) WO2010083582A1 (fr)
ZA (1) ZA201105514B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112381A1 (fr) 2015-01-09 2016-07-14 The Board Of Trustees Of The University Of Illinois Restauration de la physiologie à l'aide de petites molécules dans des organismes présentant une carence en fer
DK3684344T3 (da) 2017-10-25 2025-08-04 Chiesi Farm Spa Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
AU2003282337B2 (en) * 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
EP1601367A2 (fr) * 2003-02-06 2005-12-07 Bioresponse L.L.C. Utilisation combinee d'indoles cruciferes et de chelateurs pour le traitement d'etats lies au papillomavirus
MY151412A (en) * 2006-02-22 2014-05-30 Munnich Arnold The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
BRPI0722382A2 (pt) 2006-04-14 2012-06-05 Prana Biotechnology Ltd compostos úteis para o tratamento de cáncer
ITMI20061770A1 (it) * 2006-09-18 2008-03-19 Carlo Ghisalberti Metodo cosmetico di riduzione delle occhiaie
US8501789B2 (en) * 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease

Also Published As

Publication number Publication date
ZA201105514B (en) 2012-10-31
EP2389179A4 (fr) 2012-08-29
SG173145A1 (en) 2011-08-29
EP2389179A1 (fr) 2011-11-30
WO2010083582A1 (fr) 2010-07-29
EA201170970A1 (ru) 2012-03-30
US20130023569A1 (en) 2013-01-24
IL214291A0 (en) 2011-09-27
AU2009338093B2 (en) 2014-08-28
UA103366C2 (ru) 2013-10-10
NI201100148A (es) 2012-03-06
CA2750599A1 (fr) 2010-07-29
JP5604631B2 (ja) 2014-10-08
MA33090B1 (fr) 2012-03-01
PE20120515A1 (es) 2012-05-20
MY161269A (en) 2017-04-14
TN2011000366A1 (en) 2013-03-27
AP2011005843A0 (en) 2011-08-31
KR20120078667A (ko) 2012-07-10
JP2012515725A (ja) 2012-07-12
CN102348456A (zh) 2012-02-08
NZ594728A (en) 2013-03-28
MX2011007947A (es) 2011-12-14
CR20110456A (es) 2012-05-31
IL214291A (en) 2015-03-31
BRPI0920492A2 (pt) 2019-07-09
AU2009338093A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
NZ705624A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
HK1205461A1 (zh) 用於眼部传输治疗剂的组合物和方法
AR052172A1 (es) Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares
HK1201438A1 (en) Treatment of ocular disease
CL2014001244A1 (es) Uso de una composicion farmaceutica que comprende un derivado de 4-pregenen-11beta-17-21-triol-3,20-diona para tratar una condicion ocular tal como presion intraocular elevada, glaucoma, uveitis, degeneracion macular, retinopatia diabetica, rosacea ocular, desprendimiento de retina, entre otras.
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
MX2016009331A (es) Composiciones y metodos para tratar enfermedades oculares.
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
MX2020001644A (es) Tratamiento de afecciones oftalmicas tales como degeneracion macular, glaucoma y retinopatia diabetica usando agentes farmaceuticos que eliminan celulas senescentes.
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
MX360683B (es) Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico.
WO2013166449A3 (fr) Procédés pour le traitement de la rétinopathie diabétique et d'autres maladies ophtalmiques
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
WO2011084366A3 (fr) Procédés, compositions et systèmes d'administration de médicaments pour l'administration intraoculaire de molécules d'arnsi
ATE535243T1 (de) Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht- ergot-d2-rezeptoragonist als wirkstoff
WO2012080497A3 (fr) Procédés de traitement et de prévention de maladies oculaires
MY176525A (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
ES2722723T3 (es) Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
MX2013001870A (es) Formulaciones oftalmicas de escualamina.